NO20034648L - Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander - Google Patents
Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-liganderInfo
- Publication number
- NO20034648L NO20034648L NO20034648A NO20034648A NO20034648L NO 20034648 L NO20034648 L NO 20034648L NO 20034648 A NO20034648 A NO 20034648A NO 20034648 A NO20034648 A NO 20034648A NO 20034648 L NO20034648 L NO 20034648L
- Authority
- NO
- Norway
- Prior art keywords
- hydroxycyclyloxy
- thioxy
- hydroxytryptamine
- ligands
- aminobenzazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28564301P | 2001-04-20 | 2001-04-20 | |
| PCT/US2002/012415 WO2002085892A1 (fr) | 2001-04-20 | 2002-04-19 | Derives d'heterocyclyloxy-, -thioxy- et aminobenzazol servant de ligands de 5-hydroxytryptamine-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034648D0 NO20034648D0 (no) | 2003-10-17 |
| NO20034648L true NO20034648L (no) | 2003-11-20 |
Family
ID=23095111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034648A NO20034648L (no) | 2001-04-20 | 2003-10-17 | Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6815456B2 (fr) |
| EP (1) | EP1385842A1 (fr) |
| JP (1) | JP4323810B2 (fr) |
| KR (1) | KR20030088508A (fr) |
| CN (1) | CN1293072C (fr) |
| AR (1) | AR035235A1 (fr) |
| BR (1) | BR0209056A (fr) |
| CA (1) | CA2444095A1 (fr) |
| EA (1) | EA200301142A1 (fr) |
| EC (2) | ECSP034811A (fr) |
| HU (1) | HUP0303958A2 (fr) |
| IL (1) | IL158445A0 (fr) |
| MX (1) | MXPA03009476A (fr) |
| NO (1) | NO20034648L (fr) |
| PL (1) | PL367297A1 (fr) |
| WO (1) | WO2002085892A1 (fr) |
| ZA (1) | ZA200309004B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20033529A3 (cs) * | 2001-06-07 | 2004-04-14 | F. Hoffman-La Roche Ag | Nové deriváty indolu s afinitou k receptoru 5-HT6 |
| EP1479138A2 (fr) * | 2002-02-13 | 2004-11-24 | Koninklijke Philips Electronics N.V. | Dispositif optique a semi-conducteur integre, procede et appareil permettant de fabriquer ce dispositif |
| EP1513809A1 (fr) * | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | Derives de 1-sulfonyl-4-aminoalcoxy-indole et leur utilisation comme modulateurs des recepteurs 5-ht6 en traitement de troubles du snc |
| ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
| PL378120A1 (pl) * | 2003-02-14 | 2006-03-06 | Wyeth | Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| DE102004010132A1 (de) * | 2004-02-27 | 2005-09-15 | Merck Patent Gmbh | Piperidinderivate |
| GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| WO2006048754A1 (fr) * | 2004-11-02 | 2006-05-11 | Pfizer Japan Inc. | Dérivés de sulfonyl benzimidazole |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| BRPI0606502A2 (pt) * | 2005-01-19 | 2009-06-30 | Hoffmann La Roche | compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos |
| KR20080039994A (ko) * | 2005-08-15 | 2008-05-07 | 와이어쓰 | ５-하이드록시트립타민-６ 리간드로서의치환된-３-설포닐인다졸 |
| EP1915348A1 (fr) * | 2005-08-15 | 2008-04-30 | Wyeth a Corporation of the State of Delaware | Dérivés d azinyl-3-sulfonylindazole en tant que ligands de 5-hydroxytryptamine-6 |
| CN101432274A (zh) * | 2006-04-05 | 2009-05-13 | 惠氏公司 | 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物 |
| WO2007120596A1 (fr) * | 2006-04-12 | 2007-10-25 | Wyeth | DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6 |
| CA2650082A1 (fr) * | 2006-06-01 | 2007-12-13 | Wyeth | Derives de 1-sulfonylindazolylamine et de 1-sulfonylindazolylamide en tant que ligands de la 5-hydroxytryptamine-6 |
| WO2009006267A2 (fr) * | 2007-06-28 | 2009-01-08 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides en tant qu'intermédiaires dans la fabrication d'arylsulfonylindazoles |
| WO2009034581A1 (fr) * | 2007-09-11 | 2009-03-19 | Suven Life Sciences Limited | Composés indolyle substitués et leur utilisation en tant que ligands de 5-ht6 |
| CA2799154A1 (fr) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Inhibiteurs indazoliques des kinases |
| CN103539791B (zh) | 2010-09-22 | 2017-01-11 | 艾尼纳制药公司 | Gpr119 受体调节剂和对与其相关的障碍的治疗 |
| DK2624696T3 (en) | 2010-10-06 | 2017-03-13 | Glaxosmithkline Llc Corp Service Company | BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS |
| US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| WO2016004882A1 (fr) * | 2014-07-08 | 2016-01-14 | Sunshine Lake Pharma Co., Ltd. | Dérivés hétérocycliques aromatiques et leurs applications pharmaceutiques |
| CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| EP3582772A1 (fr) | 2017-02-16 | 2019-12-25 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| CN111233736B (zh) * | 2020-03-16 | 2021-07-16 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
| WO2024032530A1 (fr) * | 2022-08-11 | 2024-02-15 | 江苏恩华药业股份有限公司 | Dérivé de cyclohexyl aminoalkyl pipéridine hétérocyclique aromatique, son procédé de préparation et son utilisation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| JPH0940646A (ja) | 1995-07-27 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | ベンゼン縮合環誘導体又はその塩 |
| AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AU5570900A (en) * | 1999-07-01 | 2001-01-22 | Sankyo Company Limited | Indoline or tetrahydroquinoline derivatives |
| EP1196380A2 (fr) * | 1999-07-15 | 2002-04-17 | NPS Allelix Corp. | Composes heterocycliques destines au traitement de la migraine |
| IL156517A0 (en) * | 2000-12-22 | 2004-01-04 | Wyeth Corp | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| PL378120A1 (pl) * | 2003-02-14 | 2006-03-06 | Wyeth | Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy |
-
2002
- 2002-04-19 MX MXPA03009476A patent/MXPA03009476A/es active IP Right Grant
- 2002-04-19 EP EP02764248A patent/EP1385842A1/fr not_active Withdrawn
- 2002-04-19 BR BR0209056-2A patent/BR0209056A/pt not_active IP Right Cessation
- 2002-04-19 AR ARP020101442A patent/AR035235A1/es not_active Application Discontinuation
- 2002-04-19 HU HU0303958A patent/HUP0303958A2/hu unknown
- 2002-04-19 CN CNB028123085A patent/CN1293072C/zh not_active Expired - Fee Related
- 2002-04-19 CA CA002444095A patent/CA2444095A1/fr not_active Abandoned
- 2002-04-19 PL PL02367297A patent/PL367297A1/xx unknown
- 2002-04-19 KR KR10-2003-7013585A patent/KR20030088508A/ko not_active Application Discontinuation
- 2002-04-19 WO PCT/US2002/012415 patent/WO2002085892A1/fr active Application Filing
- 2002-04-19 US US10/126,598 patent/US6815456B2/en not_active Expired - Fee Related
- 2002-04-19 JP JP2002583419A patent/JP4323810B2/ja not_active Expired - Fee Related
- 2002-04-19 EA EA200301142A patent/EA200301142A1/ru unknown
- 2002-04-19 IL IL15844502A patent/IL158445A0/xx unknown
-
2003
- 2003-10-17 EC EC2003004811A patent/ECSP034811A/es unknown
- 2003-10-17 NO NO20034648A patent/NO20034648L/no not_active Application Discontinuation
- 2003-10-17 EC EC2003004810A patent/ECSP034810A/es unknown
- 2003-11-19 ZA ZA200309004A patent/ZA200309004B/en unknown
-
2004
- 2004-09-24 US US10/949,062 patent/US20050065186A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP034810A (es) | 2003-12-01 |
| IL158445A0 (en) | 2004-05-12 |
| HUP0303958A2 (hu) | 2004-04-28 |
| NO20034648D0 (no) | 2003-10-17 |
| PL367297A1 (en) | 2005-02-21 |
| CA2444095A1 (fr) | 2002-10-31 |
| ZA200309004B (en) | 2005-02-21 |
| US20030069278A1 (en) | 2003-04-10 |
| CN1293072C (zh) | 2007-01-03 |
| BR0209056A (pt) | 2004-08-10 |
| EA200301142A1 (ru) | 2004-02-26 |
| JP4323810B2 (ja) | 2009-09-02 |
| KR20030088508A (ko) | 2003-11-19 |
| MXPA03009476A (es) | 2004-02-12 |
| US6815456B2 (en) | 2004-11-09 |
| ECSP034811A (es) | 2003-12-01 |
| EP1385842A1 (fr) | 2004-02-04 |
| WO2002085892A1 (fr) | 2002-10-31 |
| JP2004526787A (ja) | 2004-09-02 |
| US20050065186A1 (en) | 2005-03-24 |
| AR035235A1 (es) | 2004-05-05 |
| CN1518547A (zh) | 2004-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034648D0 (no) | Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander | |
| DK1355904T3 (da) | Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander | |
| DK1353904T3 (da) | 1-Aryl- eller 1-alkylsulfonylbenzazolderivater som 5-hydroxytryptamin-6-ligander | |
| DK1456206T3 (da) | Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| NO20031977L (no) | 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler som 5- hydroksytryptamin-6-ligander | |
| NO20015477L (no) | 4,5,6,7-tetrahydroindazolderivater som antitumormidler | |
| NO20042279L (no) | Kinazolinderivater som antitumormidler | |
| NO20042288L (no) | Kinazolinderivater som antitumormidler | |
| MXPA03008590A (es) | Derivados del factor vii de coagulacion. | |
| ITTO20010940A0 (it) | ,,sedia,, | |
| DK1455779T3 (da) | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| NO20041316L (no) | Tiofen- og tiazoisulfonamider som antineoplastiske midler | |
| DK1355900T3 (da) | Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander | |
| NO20034647L (no) | Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander | |
| ZA200404807B (en) | Imidazoquinoline derivatives. | |
| NO20024502D0 (no) | 4-okso-1,4-dihydro-3-cinnolinkarboksamider som antivirale midler | |
| IS7131A (is) | Nýjar 2,4-díamínóþíasól afleiður | |
| DK1140851T3 (da) | 4-Oxo-1,4-dihydro-3-quinolincarboxamider som antivirale midler | |
| DK1177185T3 (da) | 4,5,6,7-tetrahydroindazolderivater som antitumormidler | |
| IS7299A (is) | 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður | |
| ES1048795Y (es) | Embalaje perfeccionado. | |
| DK1287001T3 (da) | Thiophenderivater, der er egnede som anticancermidler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |